After Structure Therapeutics (GPCR) released pivotal topline data from the Phase 2b ACCESS program, H.C. Wainwright argues that the clean safety profile along with 15.3% placebo-adjusted weight loss ...
Structure Therapeutics (GPCR) announced positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback